Instrument Inactif

Communiqués Foamix Pharmaceuticals Ltd. Nasdaq

Actions

IL0011334385

Recherche biotechnologique et médicale

Communiqués

10/07	VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
21/05	VYNE Therapeutics : Yarrow Bioscience Investor Presentation	PU
17/12	VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement	AQ
06/11	VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update	AQ
14/08/25	VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update	AQ
14/08/25	VYNE Therapeutics : Repibresib Phase 2b Vitiligo Topline Results & Additional Analyses	PU
30/07/25	VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo	AQ
30/07/25	VYNE Therapeutics : Repibresib Phase 2b Vitiligo Topline Results	PU
02/07/25	VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202	AQ
08/05/25	VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update	AQ
25/04/25	VYNE Therapeutics Provides Update on VYN202 Program	AQ
20/03/25	VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference	AQ
06/03/25	VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update	AQ
20/02/25	VYNE Therapeutics to Participate in March Investor Conferences	AQ
19/02/25	VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis	AQ
06/01/25	VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo	AQ
23/12/24	VYNE Therapeutics : Reports Positive Top line Phase 1a MAD Data for VYN202, its Novel BD2 Selective BET Inhibitor Form 8 K	PU
23/12/24	VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor	AQ
07/11/24	VYNE Therapeutics : Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K	PU
07/11/24	VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update	AQ
12/09/24	VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor	AQ
03/09/24	VYNE Therapeutics to Participate in September Investor Conferences	AQ
14/08/24	VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update	AQ
16/07/24	VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor	AQ
09/07/24	VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	AQ